Clinical trials: CVD Risk
Heart Defects, Congenital, Hyperglycemia
SPECS: Safe Pediatric Euglycemia in Cardiac Surgery
Critically ill children, including children undergoing heart surgery, commonly develop elevated blood glucose (also known as "blood sugar") levels during their illness, which can lead to poor health outcomes and an increased risk…
- Trial name
- SPECS (NCT00443599)
- Testing
- Insulin, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 989 people
- Sponsor
- Boston Children's Hospital
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents
Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol…
- Conditions
- Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol
- Trial name
- SPIRIT (NCT04807400)
- Testing
- Inclisiran, Behavioural Support, Background lipid lowering therapy
- Where
- 17 sites in United Kingdom
- Volunteers
- 892 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome
A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
In this research study we want to learn more about which treatment works better for patients diagnosed with a vascular tumor called Kaposiform Hemangioendothelioma (KHE) or other high risk vascular tumors such as Tufted Angioma…
- Conditions
- Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
- Trial name
- NCT02110069
- Testing
- Vincristine, Sirolimus
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Boston Children's Hospital
Symptomatic Severe Aortic Stenosis
FlexNav EU CE Mark Study
The purpose of this clinical investigation is to characterize the safety of the next-generation FlexNav™ Delivery System for transfemoral implantation of the Portico™ Transcatheter Aortic Heart Valve in symptomatic severe aortic…
- Trial name
- NCT03724812
- Testing
- Portico Valve and FlexNav™ Delivery System
- Where
- 6 sites in Denmark, Italy and 2 more
- Volunteers
- 46 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Myocardial Infarction
Prediction of Recurrent Events With 18F-Fluoride
This is a multi-centre observational study. It will make use of the positron emission tomography (PET) tracer 18F-sodium fluoride (18F-NaF) as a marker of coronary plaque vulnerability to detect culprit and non-culprit unstable…
- Trial name
- PREFFIR (NCT02278211)
- Where
- United Kingdom
- Volunteers
- 995 people
- Sponsor
- University of Edinburgh
Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy
Ranolazine Implantable Cardioverter-Defibrillator Trial
The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs).
- Conditions
- Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
- Trial name
- RAID (NCT01215253)
- Testing
- Ranolazine
- Where
- 90 sites in United States, Canada
- Volunteers
- 1,012 people
- Sponsor
- University of Rochester
Heart Disease
Aspirin Responsiveness in Women at Risk for Cardiac Events
The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin.
- Trial name
- NCT00818337
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Creighton University
Coronary Heart Disease
Family Heart Health Program: Randomized, Controlled Trial
Background: Family members (spouses, siblings, offspring) of patients with coronary heart disease (CHD) may themselves be at increased risk for developing CHD for genetic, biochemical and/or behavioural reasons.
- Trial name
- FHHP-RCT (NCT00552591)
- Testing
- 12-week risk reduction program, managed by a Heart Health Educator
- Where
- Canada
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Postmenopausal Osteoporosis, Gut Microbiota
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk
Aim to evaluate the effects of blackcurrant supplementation on changes in gut microbiome, bone mass, and CVD risk factors in adult women.
- Conditions
- Postmenopausal Osteoporosis, Gut Microbiota, Cardiovascular Diseases
- Trial name
- NCT04431960
- Testing
- blackcurrant (BC) extract
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation
Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction
The aim of the study is to prove that early discharge (within 72 hours) in selected group of patients after myocardial infarction with elevations of ST-segment is feasible and safe
- Conditions
- Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation, Primary Percutaneous Coronary Intervention, Early Discharge
- Trial name
- NCT02023983
- Testing
- Early discharge, Standard discharge
- Where
- Czechia
- Volunteers
- 151 people
- Sponsor
- Kamil Novobílský
Dyslipidemia, Cardiovascular Diseases
Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events
High and Very High Risk cardiovascular patient journeys seems to vary from country to country, and current understanding of the process is incomplete.
- Conditions
- Dyslipidemia, Cardiovascular Diseases, Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Trial name
- SANTORINI (NCT04271280)
- Testing
- Non-interventional
- Where
- 540 sites in Austria, Belgium and 12 more
- Volunteers
- 9,559 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Hypertension, Diabetes
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.
- Trial name
- EFFORT (NCT00829296)
- Testing
- nebivolol, Metoprolol
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Low Risk (0-10% Chance) of Developing Cardiovascular Disease Within 10 Years Based on Risk Factors, Moderate Risk (10-20% Chance) of Developing Cardiovascular (Heart) Disease Within 10 Years Based on Risk Factors
Interactive Cholesterol Advisory Tool
The purpose of this study is to show that we can effectively deliver health information and education, online, via computer regarding cholesterol. This computer program is called the Interactive Cholesterol Advisory Tool (ICAT).
- Trial name
- ICAT (NCT01890031)
- Testing
- Interactive Cholesterol Advisory Tool, Study physician visits
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- University of Rochester
STEMI, NSTEMI
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
This is a Prospective, Observational Multicenter Non-Interventional Cohort Study. The primary objective is to determine whether platelet expression of FcγRIIa is associated with risk of myocardial infarction (MI), stroke and…
- Trial name
- NCT05175261
- Testing
- Prolocor pFCG test
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Prolocor, Inc
Hypertrophic Cardiomyopathy, Sudden Cardiac Death
PRecIsion Medicine in CardiomyopathY
This is a retrospective cohort study of pediatric hypertrophic cardiomyopathy (HCM) patients using chart and registry review methodology.
- Trial name
- PRIMaCY (NCT04036799)
- Volunteers
- 572 people
- Sponsor
- The Hospital for Sick Children
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer
Myocardial Infarction
Risk Stratification in Patients With Preserved Ejection Fraction
The purpose of the study is to assess the prevalence and the prognostic value of non-invasive indexes and programmed ventricular stimulation for sudden cardiac death in post-myocardial infarction (MI) patients with left…
- Trial name
- PRESERVE-EF (NCT02124018)
- Testing
- Programmed ventricular stimulation, ICD implantation
- Where
- Greece
- Volunteers
- 575 people
- Sponsor
- University of Athens
Hypertension
Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
The overall hypothesis of this trial is that screening for chronic kidney disease, followed by education or treatment program will improve blood pressure control among hypertensive non-diabetic persons.
- Trial name
- NCT02059408
- Testing
- Screen-Educate, Screen-Educate and Intensify Treatment
- Where
- United States
- Volunteers
- 1,819 people
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Cardiovascular Diseases
Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics
The purpose of the ALL Study is to determine the effectiveness of the dissemination of the ALL intervention from an integrated care setting into Community Health Centers (CHCs) by measuring changes in diabetes mellitus (DM)…
- Trial name
- ALL (NCT02299791)
- Testing
- ALL
- Volunteers
- 4,856 people
- Sponsor
- Kaiser Permanente